HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.

Abstract
Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia.
AuthorsDavid C Currow, Amy P Abernethy
JournalFuture oncology (London, England) (Future Oncol) Vol. 10 Issue 5 Pg. 789-802 (Apr 2014) ISSN: 1744-8301 [Electronic] England
PMID24472001 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hydrazines
  • Oligopeptides
  • Receptors, Ghrelin
  • anamorelin
Topics
  • Anorexia (drug therapy, pathology)
  • Cachexia (drug therapy, pathology)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
  • Humans
  • Hydrazines (administration & dosage)
  • Oligopeptides (administration & dosage)
  • Receptors, Ghrelin (agonists, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: